NCT05214963View on ClinicalTrials.gov

Noninvasive Peripheral Nerve Stimulation for Medication-Naive and Medication-Refractory RLS

NACompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

March 8, 2022

Primary Completion Date

July 24, 2023

Study Completion Date

October 24, 2023

Conditions
Restless Legs Syndrome
Interventions
DEVICE

NTX100 Neuromodulation System - Active

Noninvasive peripheral nerve stimulation device programmed to active mode

DEVICE

NTX100 Neuromodulation System - Sham

Noninvasive peripheral nerve stimulation device programmed to sham mode

Trial Locations (3)

63123

Clayton Sleep Institute, St Louis

94025

SRI International Human Sleep Research Lab, Menlo Park

94583

Sleep Medicine Specialists of California, San Ramon

Sponsors
All Listed Sponsors
collaborator

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

lead

Noctrix Health, Inc.

INDUSTRY

NCT05214963 - Noninvasive Peripheral Nerve Stimulation for Medication-Naive and Medication-Refractory RLS | Biotech Hunter | Biotech Hunter